ClinicalTrials.gg
RecruitingNCT05953766Updated Apr 6, 2026

Presacral Nerve Block Versus Sham Block on Post-operative Pain for Total Laparoscopic Hysterectomy

A Phase 2 interventional study of Ropivacaine injection and Normal saline injection in Post-operative Pain, sponsored by Mount Sinai Hospital, Canada. Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Mount Sinai Hospital, Canada · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 184 studies testing ropivacaine in Pain, Postoperative — 20 open to participants now, 22 under way, 2 of them phase 3. Ropivacaine · Pain, Postoperative.

Planned enrollment
101st of 184
60 · median 70
Started
2025
with 5 others
Phase 2
10 of 184
3 open now
Primary completion
2026-07
later than 10 of 21 live
Registered
167th of 184
by date

Among the 184 studies testing ropivacaine in Pain, Postoperative, this one is the 101st largest by planned enrollment, is one of 6 that started in 2025, is one of 10 in phase 2, reaches primary completion later than 10 of the 21 other live ones, and was the 167th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

20 of the 184 studies testing ropivacaine in Pain, Postoperative are open now, in 10 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About ropivacaine

Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies testing ropivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

The study is a single-center parallel group randomized controlled trial comparing the administration of a presacral nerve block using 20mL of local ropivacaine 5.0mg/ml versus 20mL of normal saline (sham block) on post-operative pain following total laparoscopic hysterectomy.

Read the detailed description

The proposed study is a single-center parallel-group RCT comparing the administration of a presacral nerve block using 20mL of local ropivacaine (5.0mg/ml) versus 20mL of normal saline (sham block). This drug/dose was selected based on the recent study by Rapp et al., which instilled 20mL of ropivacaine into the presacral nerve at the time of open hysterectomy.

Participants will be selected using a convenience sample from Mount Sinai Hospital's outpatient gynecology clinics. All patients age 18 years and older undergoing total laparoscopic hysterectomy will be considered for inclusion. Exclusion criteria include: previous presacral neurectomy, concurrent surgical procedure other than salpingectomy and/or oophorectomy, gynecological cancer beyond stage 1 disease, chronic opioid consumption, fibromyalgia, BMI > 50, language barriers, inability to communicate, or inability to provide consent. All potentially eligible patients will be invited to participate in this study by their surgeon. Interested patients will then meet with a member of the research team to explain the study and obtain informed consent.

The investigators will create a randomization list using a computer-generated allocation sequence in equal ratio (1:1) to either study group with study numbers 1 to 60. A clinic nurse, unaffiliated with any other aspects of the study, who works 5 days per week in the ambulatory office and who will have no other role in this study, will prepare and label the active and placebo syringes according to the randomization list. Each syringe will be prepared individually and provided to the surgeon on the day of surgery.

Study participants will be randomized on the day of surgery. The surgeon will instill the contents from the labeled syringe (either drug/placebo) into the presacral space as the first step prior to starting the hysterectomy.

The surgeon, research team, participants, and data analysts will be blinded to treatment group.

Each study patient will receive standard of care standardized perioperative care as follows:

All patients will receive preoperative multimodal analgesia with acetaminophen 1000 mg.

A protocolized general anesthetic will be used for all patients. Induction of anesthesia will be performed with fentanyl (1-3 mcg/kg), propofol (2-3 mg/kg), and rocuronium (0.6 mg/kg), followed by endotracheal intubation. Patients will be maintained with Sevoflurane anesthetic titrated to a minimum alveolar concentration (MAC) of 0.9-1.2 in a mixture of 50:50 air/oxygen.

Analgesia will be provided with intravenous fentanyl and/or hydromorphone administered to maintain mean arterial pressure or heart rate within 20% of baseline measurements.

At skin closure, unless contraindicated, all patients will be administered intravenously ondansetron 4 mg and IV dexamethasone 0.1 mg/kg for nausea prophylaxis. Unless contraindicated, all patients will also receive intravenous ketorolac 30 mg for analgesia.

Local anesthetic will be provided at the site of the port incisions (2ml per port site of 0.25% bupivacaine with epinephrine).

Following completion of surgery, neuromuscular blockade will be antagonized with neostigmine and glycopyrrolate, and patients will be extubated and brought to the post anesthesia care unit (PACU). As per protocol and routine care, the only adjunctive analgesic administered intra-operatively in addition to opioids will be intravenous ketorolac.

Post-operative pain scores will be assessed using a self-administered numeric rating scale (NRS) for pain at 1, 2 and 3 hours after arrival in the PACU. Those patients with pain scores greater than 4/10 will receive analgesia according to a standard postoperative analgesic regimen. This will consist of intravenous fentanyl 25-50 mcg boluses every 5-10 minutes, intravenous administration of hydromorphone 0.2-0.4 mg boluses as required, and oral administration of either hydromorphone IR 1-2 mg or oxycodone IR 5-10 mg.

Rescue antiemetics will be administered if required at the discretion of the anesthesiologist in the form of IV metoclopramide 5-10 mg, ondansetron 4 mg, or dimenhydrinate 25-50 mg.

Patients will be contacted post-operatively days 1, 2 and 7 in order to collect data on post-operative pain scores, total opioid consumption, and any adverse events (secondary outcomes).

03

Conditions studied

  • Post-operative Pain

Browse trials for

Keywords

  • Hysterectomy
  • Presacral nerve block
  • Laparoscopy
  • Anesthesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Undergoing total laparoscopic hysterectomy

Exclusion criteria

Exclusion Criteria:

  • Previous presacral neurectomy
  • Concurrent surgical procedure other than salpingectomy and/or oophorectomy
  • Gynecological cancer beyond stage 1 disease
  • > 50
  • Chronic opioid consumption
  • Fibromyalgia
  • Language barrier
  • Inability to communicate and provide consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Presacral Nerve Block

    Presacral nerve block using 20mL of local ropivacaine 5.0mg/ml instilled in the presacral space

    Drug: Ropivacaine injection

  • Sham comparator
    Sham Block

    20mL of normal saline (sham block) instilled in the presacral space

    Drug: Normal saline injection

Interventions

  • DrugRopivacaineStudies of RopivacaineRopivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Presacral nerve block using 20mL of local ropivacaine 5.0mg/ml

    Also known as: Naropin

  • DrugNormal saline injection

    Sham block using 20 mL of normal saline (0.9% sodium chloride)

    Also known as: Sham block, 0.9% Sodium Chloride

06

What researchers measure

Primary outcomes

  1. Early post-operative pain at 3 hours following surgery

    Early post-operative pain measured at 3-hours following surgery by a self-administered numeric pain rating scale (NRS) on a scale from 0 to 10, with 0 indicating no pain and 10 indicating the worst pain imaginable

    Time frame: 3 hours following surgery

Secondary outcomes

  1. Post-operative pain at other time points

    Delayed post-operative pain measured by numeric pain rating scale (NRS) scores at 1 hour, 2 hour, and post-operative days 1, 2 and 7 on a scale from 0 to 10, with 0 indicating no pain and 10 indicating the worst pain imaginable

    Time frame: 1 hour, 2 hour, and post-operative days 1, 2 and 7

Other outcomes

  1. Post-operative narcotic usage

    Total narcotics administered from end of surgery until post-operative days 1, 2 and 7 (calculated from the hospital medical records and pill counts from discharge medications to be elicited by phone the day after surgery)

    Time frame: Post-operative days 1, 2 and 7

  2. Adverse effects/complication rates

    Any negative outcome that is self-reported and elicited from a telephone survey

    Time frame: Post-operative days 1, 2 and 7

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jul 2026, 10 months after the start.

Of 90 non-industry phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's planned 10 months is below that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2023
First posted
Jul 20, 2023
StartActual
Sep 24, 2025
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05953766
Responsible party
Sponsor
First posted
Jul 20, 2023
Start date
Sep 24, 2025
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Apr 6, 2026

Study contacts

Mara Sobel, MD
Contact
mara.sobel@sinaihealth.ca
416 586 8273
Shakiba Ardestani, MD
Contact
shakiba.ardestani@mail.utoronto.ca
6478185422

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion